CRA’s Walter Colasante, Pascale Diesel, and Lev Gerlovin recently published a series of three articles in Cell & Gene on emerging gene and cell therapies and their impact on the market. Read the full series below.
How are cell and gene therapies changing drug development models?
New approaches to market access and reimbursement for gene and cell therapies
Four emerging commercialization strategies for gene and cell therapies
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...